Abstract

Blindness due to diabetic retinopathy has grown to be a serious worry for all those involved in the care of diabetic ESRD patients concurrently with the pandemic expansion of diabetes as the primary cause of the condition. Macular edoema and proliferative retinopathy can contribute to vision loss. A cohort of five diabetic people who were taken from a study of erythropoietin-treated azotemic anaemic preESRD patients had their renal function, blood rheology, and the progression of diabetic eye disease reevaluated. Ophthalmologists and nephrologists work together as cotherapists to treat what has been called the diabetic renal-retinal condition due to the amazing success of laser photocoagulation in preventing irreversible vision loss in diabetes. Reduction of the chance of blindness by contemporary interventional laser surgery has been astounding [1]. For instance, a retinal screening programme has been in place in the Newcastle District of the United Kingdom since, and there, "the rates of blindness and partialsightedness are less than one-third of those reported in surveys previous to In this study, we provide our mostly anecdotal and observational experiences evaluating how eye illness responded to erythropoietin treatment in a pilot sample of anaemic, azotemic diabetic patients. The renal clinic at University Hospital of Brooklyn was asked for volunteers to participate in a study looking at how erythropoietin affects anaemia caused by renal insufficiency.

Keywords:  Diabetic retinopathy, Blindness, Erythropoietin treatment